Trial Profile
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-063
- Sponsors Merck Sharp & Dohme Corp.
- 08 Dec 2021 Results assessing the efficacy of second-line pembrolizumab in Asian patients with advanced PD L1 positive gastric/GEJ cancer, published in the Cancer.
- 31 May 2020 Status changed from active, no longer recruiting to discontinued, according to the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology